Table 8. Intermediate health outcomes (2)

| Study, year | Study group | Followup | PASI50  n/N | PASI75  n/N | PASI90  n/N | PASI100  n/N | PASI  mean(SD) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| CT5, 2012 | Etanercept | 2w  4w  8w  12w  18w  24w | 1/21  10/21  15/21  16/21  16/21  15/21 | ---  ---  ---  ---  ---  11/21 | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- | -5.38(7.13)\*  -9.98(10.64)\*  -11.11(10.89)\*  -11.97(11.63)\*  -12.13(11.67)\*  -12.16(12.15)\* |
|  | Acitretin | 2w  4w  8w  12w  18w  24w | 0/18  2/18  5/18  4/18  7/18  8/18 | ---  ---  ---  ---  ---  4/18 | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- | -3.17(5.60)\*  -4.06(5.68)\*  -6.84(9.57)\*  -6.71(6.81)\*  -8.77(8.54)\*  -9.62(10.10)\* |
| Gelfand, 2012 | MTX | --- | --- | --- | --- | --- | 3.8(1.8 to 6.6)† |
|  | Adalimumab | --- | --- | --- | -- | --- | 2.5(1.2 to 4.8)† |
|  | Etanercept | --- | --- | --- | --- | --- | 2.9(1.8 to 4.9)† |
|  | Ustekinumab | --- | --- | --- | --- | --- | 4.0(1.0 to 7.9)† |
|  | NB-UVB | --- | --- | --- | --- | --- | 3.5(2.0 to 5.5)† |
| Barker, 2011 | Infliximab | 2w  6w  10w  14w  16w  18w‡  22w‡  26w‡ | 247/653  535/653  579/653  562/653  567/653  543/653  530/653  529/653 | 59/653  365/653  487/653  473/653  508/653  488/653  473/653  502/653 | 11/653  150/653  291/653  310/653  356/653  349/653  306/653  333/653 | ---  ---  ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  ---  -85%§ |
|  | MTX | 2w  6w  10w  14w  16w  18w‡  22w‡  26w‡ | 19/215  80/215  118/215  131/215  130/215  120/215  118/215  103/215 | 1/215  31/215  58/215  85/215  90/215  85/215  82/215  66/215 | 0/215  6/215  19/215  37/215  41/215  39/215  39/215  32/215 | ---  ---  ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  ---  ---  -54%§ |
|  | Infliximab transitioned to MTX | 18w  22w  26w | ---  ---  --- | 0/9  1/9  1/9 | 0/9  0/9  0/9 | ---  ---  --- | ---  ---  --- |
|  | MTX transitioned to infliximab | 18w  22w  26w | ---  ---  --- | 15/63  38/63  46/63 | 5/63  17/63  30/63 | ---  ---  --- | ---  ---  --- |
| Emerit, 2011 | Etanercept | 0w  12w  32w | ---  ---  --- | ---  ---  --- | ---  ---  --- | ---  ---  --- | 21.4(6.1)  3.7(1.2)  --- |
|  | Infliximab | 0w  12w  32w | ---  ---  --- | ---  ---  --- | ---  ---  --- | ---  ---  --- | 22.3(6.5)  2.1(0.7)  --- |
|  | PUVA | 0w  12w  32w | ---  ---  --- | ---  ---  --- | ---  ---  --- | ---  ---  --- | 21.9(6.3)  2.2(1.1)  7.3(1.8) |
|  | NB-UVB | 0w  12w  32w | ---  ---  --- | ---  ---  --- | ---  ---  --- | ---  ---  --- | 21.3(5.2)  3.7(1.2)  10.8(2.2) |
| Inzinger, 2011|| | Adalimumab | 12w | 13/18 | 10/18 | 4/18 | 1/18 | --- |
|  | Alefacept | 12w | 20/32 | 8/32 | 1/32 | 1/32 | --- |
|  | Etanercept | 12w | 32/38 | 15/38 | 11/38 | 2/38 | --- |
|  | Infliximab | 12w | 7/7 | 7/7 | 5/7 | 2/7 | --- |
|  | Ustekinumab | 12w | 16/18 | 12/18 | 7/18 | 1/18 | --- |
|  | PUVA | 10.3w¶ | 65/71 | 63/71 | 50/71 | 15/71 | --- |
| Strober, 2011 | MTX transitioned to adalimumab | 0w  2w  4w  8w  16w | ---  ---  ---  ---  --- | ---  ---  ---  ---  --- | ---  ---  ---  ---  --- | ---  ---  ---  ---  --- | 10.8(NR)  6.9(NR)  5.4(NR)  3.4(NR)  2.3(NR) |
|  | NB-UVB transitioned to adalimumab | 0w  2w  4w  8w  16w | ---  ---  ---  ---  --- | ---  ---  ---  ---  --- | ---  ---  ---  ---  --- | ---  ---  ---  ---  --- | 12.4(NR)  9.1(NR)  6.7(NR)  4.1(NR)  3.6(NR) |
| Garavaglia, 2010 | CyA transitioned to etanercept | --- | --- | --- | --- | --- | --- |
| Caproni, 2009 | Etanercept | 12w | 26/30 | 17/30 | --- | --- | 4.61(2.75) |
|  | Acitretin | 12w | 20/30 | 8/30 | --- | --- | 9.62(4.64) |
| Mazzotta, 2009 | Nonbiologics or phototherapy transitioned to etanercept\*\* | 12w  24w | 79/98  88/98 | 43/98  74/98 | ---  --- | ---  --- | 4.9(4.0)  2.8(3.4) |
| Gisondi, 2008a | Etanercept | 6w  12w  18w  24w | 6/22  9/22  11/22  15/22 | 2/22  5/22  8/22  10/22 | ---  ---  ---  --- | ---  ---  ---  --- | ---  ---  ---  --- |
|  | Acitretin | 6w  12w  18w  24w | 2/20  4/20  7/20  10/20 | 1/20  2/20  2/20  6/20 | ---  ---  ---  --- | ---  ---  ---  --- | ---  ---  ---  --- |
| Gisondi, 2008b | Etanercept | 24w | --- | --- | --- | --- | 4.8(4.7)  -74.5%§ |
|  | Infliximab | 24w | --- | --- | --- | --- | 2.1(3.2)  -88.8%§ |
|  | MTX | 24w | --- | --- | --- | --- | 4.3(6.0)  -47.1%§ |
| Saurat, 2008 | Adalimumab | 2w  4w  8w  12w  16w | ---  73/108  88/108  98/108  95/108 | 5/108  25/108  67/108  83/108  86/108 | ---  7/108  29/108  52/108  56/108 | ---  1/108  9/108  12/108  18/108 | ---  ---  ---  ---  -16.7(8.8)\* |
|  | MTX | 2w  4w  8w  12w  16w | ---  17/110  42/110  60/110  68/110 | 0/110  3/110  10/110  27/110  39/110 | ---  1/110  3/110  10/110  15/110 | ---  1/110  0/110  1/110  8/110 | ---  ---  ---  ---  -10.9(8.3)\* |
|  | MTX transitioned to adalimumab | 0w  24w | ---  --- | 26/95  70/95 | 13/95  50/95 | 5/95  30/95 | ---  --- |
| Magliocco, 2007 | CyA transitioned to alefacept | --- | --- | --- | --- | --- | --- |
| Costanzo, 2005 | Nonbiologics transitioned to etanercept†† | 12w  24w | 28/44  12/15 | 19/44  10/15 | 4/44  6/15 | ---  --- | 7.5(NR)  -52%§  4.3(NR)  -72%§ |

Abbreviations: CyA=cyclosporine; MTX=methotrexate; n/N=number of patients per total population; NB-UVB=narrowband ultraviolet B; NR=not reported; PASI=Psoriasis Area and Severity Index; PUVA=psoralen plus ultraviolet A; w=week(s); ---=not reported

\* Mean(SD) change from baseline

† Median (IQR)

‡ Includes patients who switched treatments at week 16 as nonresponders

§ Mean percentage change from baseline

|| Results reported out of treatment courses, not patients. Patients could have more than one treatment course

¶ End of phototherapy treatment, median 10.3w

\*\* Nonbiologics included CyA, corticosteroids, MTX, retinoids

†† Nonbiologics included CyA, corticosteroids, fumaric acid esters, MTX, retinoids, PUVA